Operating Income (Loss) in USD of XBiotech Inc. from 2013 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
XBiotech Inc. quarterly/annual Operating Income (Loss) history and change rate from 2013 to Q3 2025.
  • XBiotech Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$6,047,000.000, a 23.5% increase year-over-year.
  • XBiotech Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$34,681,000.000, a 18% increase year-over-year.
  • XBiotech Inc. annual Operating Income (Loss) for 2024 was -$42,471,000.000, a 13.2% decline from 2023.
  • XBiotech Inc. annual Operating Income (Loss) for 2023 was -$37,510,000.000, a 8.76% decline from 2022.
  • XBiotech Inc. annual Operating Income (Loss) for 2022 was -$34,490,000.000, a 37.5% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

XBiotech Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$34,681,000 -$6,047,000 +$1,857,000 +23.5% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025
Q2 2025 -$36,538,000 -$6,336,000 +$8,630,000 +57.7% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025
Q1 2025 -$45,168,000 -$13,550,000 -$2,697,000 -24.8% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025
Q4 2024 -$42,471,000 -$8,748,000 -$160,000 -1.9% 01 Oct 2024 31 Dec 2024 10-K 18 Mar 2025
Q3 2024 -$42,311,000 -$7,904,000 +$616,000 +7.2% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025
Q2 2024 -$42,927,000 -$14,966,000 -$1,708,000 -12.9% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025
Q1 2024 -$41,219,000 -$10,853,000 -$3,708,000 -51.9% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025
Q4 2023 -$37,511,000 -$8,588,000 -$426,000 -5.2% 01 Oct 2023 31 Dec 2023 10-K 15 Mar 2024
Q3 2023 -$37,085,000 -$8,520,000 -$2,131,000 -33.4% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024
Q2 2023 -$34,954,000 -$13,258,000 -$1,164,000 -9.6% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024
Q1 2023 -$33,790,000 -$7,145,000 +$700,000 +8.9% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024
Q4 2022 -$34,490,000 -$8,162,000 -$969,000 -13.5% 01 Oct 2022 31 Dec 2022 10-K 15 Mar 2024
Q3 2022 -$33,521,000 -$6,389,000 -$2,658,000 -71.2% 01 Jul 2022 30 Sep 2022 10-K 15 Mar 2024
Q2 2022 -$30,863,000 -$12,094,000 -$1,489,000 -14% 01 Apr 2022 30 Jun 2022 10-K 15 Mar 2024
Q1 2022 -$29,374,000 -$7,845,000 -$4,292,000 -1.2% 01 Jan 2022 31 Mar 2022 10-K 15 Mar 2024
Q4 2021 -$25,082,000 -$7,193,000 -$2,271,000 -46.1% 01 Oct 2021 31 Dec 2021 10-K 15 Mar 2023
Q3 2021 -$22,811,000 -$3,731,000 +$939,000 +20.1% 01 Jul 2021 30 Sep 2021 10-K 15 Mar 2023
Q2 2021 -$23,750,000 -$10,605,000 -$4,091,000 -62.8% 01 Apr 2021 30 Jun 2021 10-K 15 Mar 2023
Q1 2021 -$19,659,000 -$3,553,000 -$1,382,000 -63.7% 01 Jan 2021 31 Mar 2021 10-K 15 Mar 2023
Q4 2020 -$18,277,000 -$4,922,000 +$8,389,000 +63% 01 Oct 2020 31 Dec 2020 10-K 15 Mar 2022
Q3 2020 -$26,666,000 -$4,670,000 +$1,441,000 +23.6% 01 Jul 2020 30 Sep 2020 10-K 15 Mar 2022
Q2 2020 -$28,107,000 -$6,514,000 -$508,000 -8.5% 01 Apr 2020 30 Jun 2020 10-K 15 Mar 2022
Q1 2020 -$27,599,000 -$2,171,000 +$3,634,000 +62.6% 01 Jan 2020 31 Mar 2020 10-K 15 Mar 2022
Q4 2019 -$31,233,000 -$13,311,000 -$7,203,000 -1.2% 01 Oct 2019 31 Dec 2019 10-K 16 Mar 2021
Q3 2019 -$24,030,000 -$6,111,000 -$996,000 -19.5% 01 Jul 2019 30 Sep 2019 10-K 16 Mar 2021
Q2 2019 -$23,034,000 -$6,006,000 -$385,000 -6.8% 01 Apr 2019 30 Jun 2019 10-K 16 Mar 2021
Q1 2019 -$22,649,000 -$5,805,000 -$1,655,000 -39.9% 01 Jan 2019 31 Mar 2019 10-K 16 Mar 2021
Q4 2018 -$20,994,000 -$6,108,000 +$1,399,000 +18.6% 01 Oct 2018 31 Dec 2018 10-K 16 Mar 2020
Q3 2018 -$22,393,000 -$5,115,000 +$1,478,000 +22.4% 01 Jul 2018 30 Sep 2018 10-K 16 Mar 2020
Q2 2018 -$23,871,000 -$5,621,000 +$4,067,000 +42% 01 Apr 2018 30 Jun 2018 10-K 16 Mar 2020
Q1 2018 -$27,938,000 -$4,150,000 +$6,121,000 +59.6% 01 Jan 2018 31 Mar 2018 10-K 16 Mar 2020
Q4 2017 -$34,059,000 -$7,507,000 +$8,934,000 +54.3% 01 Oct 2017 31 Dec 2017 10-K/A 15 Mar 2019
Q3 2017 -$42,993,000 -$6,593,000 +$5,866,000 +47.1% 01 Jul 2017 30 Sep 2017 10-K/A 15 Mar 2019
Q2 2017 -$48,859,000 -$9,688,000 +$3,927,000 +28.8% 01 Apr 2017 30 Jun 2017 10-K/A 15 Mar 2019
Q1 2017 -$52,786,000 -$10,271,000 -$23,000 -0.22% 01 Jan 2017 31 Mar 2017 10-K/A 15 Mar 2019
Q4 2016 -$52,763,000 -$16,441,000 +$30,099,000 +64.7% 01 Oct 2016 31 Dec 2016 10-K 16 Mar 2018
Q3 2016 -$82,862,000 -$12,459,000 -$23,273,000 -2.2% 01 Jul 2016 30 Sep 2016 10-K 16 Mar 2018
Q2 2016 -$59,589,000 -$13,615,000 -$20,036,000 -3.1% 01 Apr 2016 30 Jun 2016 10-K 16 Mar 2018
Q1 2016 -$39,553,000 -$10,248,000 -$2,043,000 -24.9% 01 Jan 2016 31 Mar 2016 10-K 16 Mar 2018
Q4 2015 -$37,510,000 -$46,540,000 -$40,151,000 -6.3% 01 Oct 2015 31 Dec 2015 10-K 16 Mar 2018
Q3 2015 $2,641,000 $10,814,000 +$17,794,000 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016
Q2 2015 -$15,153,000 $6,421,000 +$10,326,000 01 Apr 2015 30 Jun 2015 10-Q 12 Aug 2016
Q1 2015 -$25,479,000 -$8,205,000 -$3,701,000 -82.2% 01 Jan 2015 31 Mar 2015 10-Q 13 May 2016
Q4 2014 -$21,778,000 -$6,389,000 01 Oct 2014 31 Dec 2014 10-K 16 Mar 2017
Q3 2014 -$6,980,000 01 Jul 2014 30 Sep 2014 10-Q 13 Nov 2015
Q2 2014 -$3,905,000 01 Apr 2014 30 Jun 2014 10-Q 14 Aug 2015
Q1 2014 -$4,504,000 01 Jan 2014 31 Mar 2014 10-Q 18 Jun 2015

XBiotech Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$42,471,000 -$4,961,000 -13.2% 01 Jan 2024 31 Dec 2024 10-K 18 Mar 2025
2023 -$37,510,000 -$3,020,000 -8.8% 01 Jan 2023 31 Dec 2023 10-K 18 Mar 2025
2022 -$34,490,000 -$9,408,000 -37.5% 01 Jan 2022 31 Dec 2022 10-K 15 Mar 2024
2021 -$25,082,000 -$6,806,000 -37.2% 01 Jan 2021 31 Dec 2021 10-K 15 Mar 2023
2020 -$18,276,000 +$12,957,000 +41.5% 01 Jan 2020 31 Dec 2020 10-K 15 Mar 2022
2019 -$31,233,000 -$10,239,000 -48.8% 01 Jan 2019 31 Dec 2019 10-K 15 Mar 2022
2018 -$20,994,000 +$13,065,000 +38.4% 01 Jan 2018 31 Dec 2018 10-K 16 Mar 2021
2017 -$34,059,000 +$18,704,000 +35.4% 01 Jan 2017 31 Dec 2017 10-K 16 Mar 2020
2016 -$52,763,000 -$15,253,000 -40.7% 01 Jan 2016 31 Dec 2016 10-K/A 15 Mar 2019
2015 -$37,510,000 -$15,732,000 -72.2% 01 Jan 2015 31 Dec 2015 10-K 16 Mar 2018
2014 -$21,778,000 -$11,853,000 -1.2% 01 Jan 2014 31 Dec 2014 10-K 16 Mar 2017
2013 -$9,925,000 01 Jan 2013 31 Dec 2013 10-K 15 Apr 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.